What is REPH's gross margin?

Recro Pharma (REPH) has a gross margin of 28% and a net margin of -3%.

What is REPH's P/E ratio?

Track Recro Pharma (REPH) P/E ratio, ROE, and valuation metrics over time.

Where can I see REPH's full financials?

See Recro Pharma (REPH) income statement, cash flow, and balance sheet — quarterly and annual — alongside insider trading activity.

Recro Pharma (REPH) Financials — Revenue, Earnings, Cash Flow

$2.09

Last traded 2022-03-21 — delisted

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $177.4M mcap · 70M float · 0.184% daily turnover

Overview News Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Dividends Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

📊 Key Metrics

TTM

$95M

Revenue

+12.0% YoY

$-22M

Net Income

+8.5% YoY

$-11M

Free Cash Flow

-147.8% YoY

27.8%

Gross Margin

21.3%

Op. Margin

-2.8%

Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-44.8%

ROA-14.0%

ROIC-28.3%

Valuation

P/E-14.9

P/B3.4

EV/EBITDA-6.2

Leverage

Debt/Equity0.72

Current Ratio1.07

Interest Cov.-1.7x

Quality Scores

Piotroski F4/9

Altman Z-1.55

Beneish M-3.14